Clinical activity of ixabepilone, a novel epothilone b analog, across the breast cancer disease continuum

Ixabepilone is a semi-synthetic analog of epothilone B which has a low susceptibility to multiple mechanisms of resistance. Ixabepilone has been evaluated both as a single agent and as combination therapy in more than 1,200 patients across the continuum of breast cancer – as primary systemic therapy in patients with locally-advanced and metastatic breast cancer: first line in taxane-naive and taxane-resistant patients, second and third line in taxane-resistant or -naive patients, third or fourth line in multi-resistant patients. Ixabepilone is effective in patients as a neoadjuvant therapy. Ixabepilone has effic…